Neonatal Antibiotic Exposure and Neonatal Unit Admission in Infants Born to Mothers with Peripartum Bacteraemia: An Eight-Year Retrospective Cohort Study
This eight-year retrospective cohort study of 104 maternal peripartum bacteraemia cases found that while the condition caused significant maternal morbidity, it resulted in no culture-confirmed early-onset neonatal sepsis among liveborn infants, suggesting that current high rates of antibiotic exposure and mother-infant separation for well, term infants may be unnecessary and warrant antimicrobial stewardship interventions.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a mother develops a bloodstream infection around the time of childbirth, the medical world treats it as a serious warning sign. This condition, known as peripartum bacteraemia, is rare but dangerous for the mother, often causing severe illness. Because the bacteria causing the infection can pass to the baby, doctors have long followed a strict rule: any infant born to a mother with this infection must be separated from her, admitted to a special care nursery, and treated with antibiotics immediately. This approach is designed to catch early-onset neonatal sepsis, a life-threatening infection that can strike newborns within their first few days of life. However, this protective strategy comes with a heavy cost. It separates mothers and babies during a critical bonding period, exposes healthy infants to powerful drugs that can disrupt their developing gut bacteria, and fills neonatal units with babies who may not actually be sick. The medical community has long debated whether this blanket approach is necessary for every single case, especially when the mother's infection is confirmed by laboratory tests but the baby appears perfectly healthy.
To answer this question, researchers at the National Maternity Hospital in Dublin looked back at eight years of medical records, from 2018 to 2025. They focused on every instance where a mother had a confirmed bloodstream infection during the window of time just before and just after delivery. They identified 104 such cases among more than 64,000 births. The team carefully tracked what happened to these mothers and their babies, noting the specific types of bacteria involved, how sick the mothers became, and exactly how the infants were managed. They wanted to see if the standard practice of treating every exposed baby with antibiotics and moving them to the nursery was actually preventing confirmed infections, or if it was simply treating babies who were never in danger.
The study revealed that while the mothers faced significant health challenges, the babies fared remarkably well. About one in ten mothers became severely ill, with some requiring intensive care, but there were no deaths among the mothers. The most common bacteria found were Escherichia coli, group B streptococcus, and a group known as viridans streptococci. When the researchers looked at the 94 live-born infants, they found a striking result: not a single baby had a culture-confirmed infection. In medical terms, this means that when doctors took blood samples from the babies to look for bacteria, every single test came back negative. Even more telling, none of the live-born babies died.
Despite this clean bill of health for the infants, the standard protocol was followed in almost every case. Nearly 90 percent of the babies received antibiotics, and more than 70 percent were admitted to the neonatal unit, separated from their mothers. This separation happened even when the babies showed no signs of illness. The researchers found that the vast majority of these infants remained perfectly healthy throughout their hospital stay. Among the 55 babies who never showed any symptoms of sickness, 46 still received antibiotics, and 29 were still separated from their mothers simply because their mothers had an infection. While no live-born infant had a confirmed infection, the study did find that some babies developed clinical signs of illness; notably, four of the premature infants developed clinical early-onset sepsis, whereas only one full-term baby did.
The findings suggest that the current practice of automatically treating and separating all infants born to mothers with confirmed bloodstream infections may be overly cautious. The study showed that while the mothers' infections were serious, they did not translate into confirmed infections for the babies, even when the mothers were very sick. The researchers noted that the antibiotics given to the mothers before delivery might have helped protect the babies, but they also pointed out that the high rate of antibiotic use in healthy newborns contributes to a growing problem of drug resistance and disrupts the natural development of a baby's microbiome. The data indicates that for full-term babies who appear healthy, the risk of infection is so low that the routine separation and treatment might be unnecessary.
This research does not claim that doctors should ignore mothers with infections or stop treating sick babies. Instead, it highlights a clear opportunity to change how healthy, full-term infants are managed. The authors suggest that a more selective approach, where well-appearing babies are observed closely rather than immediately treated with drugs and separated from their mothers, could be safe and beneficial. By focusing on the actual health of the infant rather than just the mother's diagnosis, hospitals could reduce unnecessary medical interventions, keep families together, and preserve the effectiveness of antibiotics for when they are truly needed. The study provides a strong foundation for rethinking these protocols, offering evidence that the current high level of intervention may not be justified for the majority of these infants.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.